Schering-Plough’s Bridion Goes Before Anesthesia Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
Sugammadex, under review for reversal of neuromuscular blockade, has an action date in the second quarter.
You may also be interested in...
Anesthesia Advisory Committee To Review Schering-Plough’s Bridion For Novel Indication
Schering seeks ‘immediate effectiveness’ approval for the relaxant binding agent.
Anesthesia Advisory Committee To Review Schering-Plough’s Bridion For Novel Indication
Schering seeks ‘immediate effectiveness’ approval for the relaxant binding agent.
Schering-Plough Makes Its Move, Snapping Up Organon For $14.4 Billion
After much talk of a major acquisition, Schering buys the Organon pharmaceutical and animal health business of Akzo Nobel.